Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus chemotherapy with or without upfront stereotactic radiotherapy for NSCLC brain metastases
NL-OMON61741Phase 2Not yet recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 2026
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ivonescimab and pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Intracranial progression-free survival. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
ivonescimabpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON61741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61741.